/ Medical Professionals

Pipeline

Rigorous and groundbreaking science has always been at the core of what we do at Genentech. Our R&D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics.


Displaying
46
MOLECULES
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
       
Managed by Roche
Molecule Indication Phase
Alectinib ALK+ metastatic non-small cell lung cancer *
Anti-CD20/CD3 TDB Hematologic malignancies
Anti-Ly6E ADC HER2-negative breast cancer and non-small cell lung cancer
Anti-OX40 MAb Solid tumors
Antibody drug conjugate Pancreatic and ovarian cancers
Antibody drug conjugate Non-Hodgkin's lymphoma
Atezolizumab Solid tumors *
Metastatic melanoma *
Bevacizumab

1st line glioblastoma multiforme

*

1st line metastatic ovarian cancer

*

Adjuvant breast cancer, HER2-negative

*

Adjuvant breast cancer, HER2-positive

*

Adjuvant non-small cell lung cancer

*

High-risk carcinoid

*
ChK1 Inhibitor (GDC-0575)

Solid tumors

Cobimetinib Solid tumors *
Metastatic melanoma *
Duligotuzmab Solid tumors with mutant KRAS
ERK Inhibitor (GDC-0994) Solid tumors
Erlotinib

1st line metastatic non-small cell lung cancer, EGFR mutation positive

*
IDO Inhibitor (GDC-0919) Solid tumors
Ipatasertib Solid tumors
Gastric cancer
Triple negative breast cancer
Prostate cancer
Obinutuzumab

Diffuse large B-cell lymphoma

*

Front-line indolent non-Hodgkin's lymphoma

*

Refractory indolent Non Hodgkin's lymphoma

*

Front-line chronic lymphocytic leukemia

*
Pertuzumab

Early HER2-positive breast cancer

*

HER2-positive gastric cancer

*

2nd line HER2-positive metastatic breast cancer

*
Polatuzumab vedotin Non-Hodgkin's lymphoma and diffuse large B-cell lymphoma *
SERD (GDC-0810) ER+ HER2-negative breast cancer
SERD (GDC-0927) ER+ HER2-negative breast cancer
Taselisib HER2-negative metastatic breast cancer *
Solid tumors and HR+ breast cancer *
Trastuzumab emtansine

1st line HER2-positive metastatic breast cancer

*

3rd line HER2-positive metastatic breast cancer

*
Vemurafenib

Adjuvant metastatic melanoma, BRAF mutation positive

*

Papillary thyroid cancer, BRAF mutation positive

*

Metastatic melanoma, BRAF mutation positive

*
Venetoclax

Chronic lymphocytic leukemia and non-Hodgkin's lymphoma

*
Vismodegib

Operable basal cell carcinoma

*
BTK Inhibitor (GDC-0853) Autoimmune diseases
Etrolizumab Ulcerative colitis *
GDC-3280 Fibrosis
IL22-Fc Inflammatory diseases
Lebrikizumab

Severe asthma

*
Obinutuzumab Lupus Nephritis
Rituximab Pemphigus Vulgaris
Sodium Hyaluronate

Enthesopathy

*
Tocilizumab Early rheumatoid arthritis *
Systemic sclerosis *
Giant Cell Arteritis *
Crenezumab Alzheimer's Disease *
Gantenerumab Alzheimer's Disease *
Nav1.7 Inhibitor (GDC-0276) Pain
Nav1.7 Inhibitor (GDC-0310) Pain
Ocrelizumab

Primary progressive multiple sclerosis

*

Relapsing multiple sclerosis

*
Anti-FGFR1/KLB Mab Type 2 diabetes
Tofogliflozin

Type 2 diabetes

*
Anti-Influenza A MAb Severe influenza
Anti-Influenza B MAb Severe influenza
New Molecular Entity Infectious disease
Lampalizumab Geographic atrophy associated with advanced age-related macular degeneration *
Ranibizumab

Sustained delivery age-related macular degeneration

*
No molecules match your search.

Accessing Investigational Medicines

Learn how patients gain access to medicines before they are FDA-approved…

Partner with Us

Approximately 50% of our pipeline and marketed products involve some kind of collaboration…